Hepatology — Publications
Resources and insights tagged ta hepatology from Pedestal Health.
Publications
78
Total Publications
19
Abstract/Manuscript
7
Oral Presentation
52
Poster Presentation
2026 · Poster Presentation · Hepatology
Leveraging AI-driven natural language processing to enhance symptom capture in primary biliary Cholangitis (PBC) and primary Sclerosing Cholangitis (PSC)
Read more →2026 · Poster Presentation · Hepatology
Analysis of Structured and Unstructured Data From a Large Electronic Health Record System Identifies Frequent Pruritus and Fatigue in Patients With PSC
Read more →2025 · Poster Presentation · Genentech · Hepatology
Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry
Read more →2025 · Poster Presentation · Merck · Hepatology
Real-World Treatment Patterns Among US Adults with Unresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT)
Read more →2025 · Abstract/Manuscript · UNC
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH
Read more →2025 · Abstract/Manuscript · Kings College of London
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease
Read more →2025 · Abstract/Manuscript
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy
Read more →2025 · Poster Presentation · University of Miami (FL) · Hepatology
Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease
Read more →2025 · Poster Presentation · Saint Louis University · Hepatology
Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort
Read more →2025 · Poster Presentation · Madrigal · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions
Read more →2025 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 Diabetes and Obesity are The Main Metabolic Risk Factors for The Development of Cirrhosis in People with Metabolic Dysfunction Associated Steatohepatitis
Read more →2024 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status
Read more →2024 · Poster Presentation · UNC · Hepatology
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Merck · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort
Read more →2024 · Poster Presentation · Merck · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort
Read more →2024 · Poster Presentation · Novo Nordisk · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups
Read more →2024 · Poster Presentation · UNC · Hepatology
Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH
Read more →2024 · Poster Presentation · Saint Louis University · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Madrigal · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score
Read more →2024 · Poster Presentation · Madrigal · Hepatology
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH
Read more →2024 · Poster Presentation · University of Miami (FL) · Hepatology
Complication-Free Survival in a Real-World Cohort of PBC Patients: Deep Versus Adequate ALP Response to UDCA
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
Read more →2024 · Abstract/Manuscript · Heinrich Heine University Dusseldorf/German Diabetes Center
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort
Read more →2024 · Poster Presentation · Heinrich Heine University Düsseldorf · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH
Read more →2024 · Oral Presentation · Saint Louis University · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality
Read more →2023 · Poster Presentation · University of Birmingham / NIHR Birmingham BRC · Hepatology
NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US
Read more →2023 · Poster Presentation · Cleveland Clinic · Hepatology
A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS
Read more →2023 · Abstract/Manuscript · National University Hospital
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Read more →2023 · Abstract/Manuscript · Mayo Clinic
Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary
Read more →2023 · Oral Presentation · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study
Read more →2022 · Poster Presentation · Saint Louis University · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH
Read more →2022 · Poster Presentation · Novartis · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks
Read more →2022 · Abstract/Manuscript · Emory
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease
Read more →2022 · Abstract/Manuscript · Mayo Clinic
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
Read more →2022 · Oral Presentation · Hepatology
Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC (APASL)
Read more →2022 · Oral Presentation · Hepatology
The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC (APASL)
Read more →2021 · Poster Presentation · AbbVie · Hepatology
Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · University of Michigan
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · University of Michigan
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort
Read more →2021 · Abstract/Manuscript · Zucker School of Medicine at Hofstra
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
Read more →2020 · Poster Presentation · University of Miami (FL) · Hepatology
A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes
Read more →2020 · Poster Presentation · Heinrich-Heine University Düsseldorf · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice
Read more →2020 · Poster Presentation · UNC · Hepatology
Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study
Read more →2020 · Poster Presentation · Novartis · Hepatology
Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH
Read more →2020 · Poster Presentation · Hepatology
The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC
Read more →2020 · Poster Presentation · Hepatology
Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC
Read more →2020 · Abstract/Manuscript · University of Michigan
Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease
Read more →2020 · Abstract/Manuscript · University of Michigan
Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases
Read more →2020 · Abstract/Manuscript · University of Michigan
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC
Read more →2020 · Oral Presentation · Hepatology
Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus
Read more →2020 · Oral Presentation · Hepatology
Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH
Read more →2019 · Poster Presentation · University of Michigan · Hepatology
Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort
Read more →2019 · Poster Presentation · Emory · Hepatology
Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH
Read more →2019 · Poster Presentation · Emory · Hepatology
Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH
Read more →2019 · Poster Presentation · University of Michigan · Hepatology
The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease
Read more →2019 · Poster Presentation · University of Michigan · Hepatology
Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity
Read more →2019 · Poster Presentation · University of Michigan · Hepatology
Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD
Read more →2019 · Poster Presentation · University of Miami (FL) · Hepatology
Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real-world cohort (DDW 2019)
Read more →2019 · Poster Presentation · University of Miami (FL) · Hepatology
Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort (DDW 2019)
Read more →2019 · Poster Presentation · Saint Louis University · Hepatology
Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC)
Read more →2019 · Poster Presentation · Saint Louis University · Hepatology
Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US
Read more →2019 · Poster Presentation · Zucker School of Medicine at Hofstra · Hepatology
Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study (AASLD)
Read more →2019 · Oral Presentation · Hepatology
Incidence of Achieving Weight Loss Goals in Usual Clinical Practice: Results for the TARGET-NASH Observational Cohort
Read more →2018 · Poster Presentation · Emory · Hepatology
Characterization of polypharmacy in patients with NAFLD
Read more →2018 · Poster Presentation · Columbia University Medical Center · Hepatology
Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM)
Read more →2018 · Poster Presentation · University of Michigan · Hepatology
Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH
Read more →2018 · Poster Presentation · University of Michigan · Hepatology
Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)
Read more →2018 · Poster Presentation · University of Texas Southwestern · Hepatology
Patient-Reported Indicators of Health and Symptoms in US Patients with Primary Biliary Cholangitis (PBC)
Read more →2018 · Poster Presentation · Stanford · Hepatology
Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (DDW)
Read more →2018 · Poster Presentation · Stanford · Hepatology
Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC (DDW)
Read more →2018 · Abstract/Manuscript
A Real-World Observational Cohort of Patients with Primary Biliary Cholangitis: TARGET-PBC Study Design and Rationale
Read more →2017 · Poster Presentation · University of Michigan · Hepatology
Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH
Read more →2017 · Poster Presentation · University of Michigan · Hepatology